alexa Preclinical and First-In-Human Phase I Clinical Evaluation of Stampidine, a Potent Anti-HIV Pharmaceutical Drug Candidate
ISSN 2155-6113

Journal of AIDS & Clinical Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Preclinical and First-In-Human Phase I Clinical Evaluation of Stampidine, a Potent Anti-HIV Pharmaceutical Drug Candidate

Pedro Cahn1,2,3*, Maria Jose Rolon2, Ana Mirta Gun2, Ines Ferrari4, Ilker Dibirdik5,6, Sanjive Qazi5,6, Osmond D'Cruz5,6,8, Kazim Sahin7 and Fatih Uckun6,8,9*

1Department of Medicine, Buenos Aires University Medical School, Buenos Aires, Argentina

2Infectious Diseases Unit, Hospital Juan A. Fernández, Buenos Aires, Argentina

3Fundación Huesped,m Buenos Aires, Argentina

4Laboratorio de Bioequivalencia y Biologia Molecular, Universidad Barceló. French 2464 – Ciudad Autonoma de Buenos Aires, Argentina

5Paradigm Pharmaceuticals, St. Paul, Minnesota 55455, Drug Discovery Program, USA

6Parker Hughes Institute, St. Paul, MN 55455, USA

7Faculty of Veterinary Science and Department of Nutrition, Firat University, Elazig, Turkey

8Developmental Therapeutics Program, Children’s Hospital Los Angeles, Children’s Center for Cancer and Blood Diseases, Los Angeles, CA 90027, USA

9Department of Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA

*Corresponding Author:
Fatih M. Uckun, M.D., Ph.D.,
Children’s Center for Cancer and Blood Diseases
Children’s Hospital Los Angeles, MS#57, Los Angeles
California 90027-0367, USA
Tel: (323)-361-4328
Fax: 323-361-876
E-mail: [email protected]

Pedro Cahn, M.D, Ph.D.,
Fundación Huesped
Angel Peluffo 3932 (C1202ABB) Buenos Aires, Argentina
E-mail: [email protected]

Received Date: December 22, 2011; Accepted Date: January 20, 2012; Published Date: January 24, 2012

Citation: Cahn P, Rolon MJ, Gun AM, Ferrari I, Dibirdik I, et al. (2012) Preclinical and First-In-Human Phase I Clinical Evaluation of Stampidine, a Potent Anti-HIV. J AIDS Clinic Res 3:138. doi:10.4172/2155-6113.1000138

Copyright: © 2012 Cahn P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



The rationally designed novel anti-HIV drug candidate Stampidine exhibited (a) remarkable subnanomolar to low nanomolar in vitro ARV potency against genotypically and phenotypically NRTI-resistant primary clinical HIV isolates, non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 isolates, clinical non-B subtype HIV- 1 isolates (subtypes A, C, F, and G) originating from South America, Asia, and sub-Saharan Africa with resistance to stavudine, adefovir and tenofovir, as well as recombinant HIV clones containing common patterns of RT mutations responsible for NRTI resistance such as multiple TAMs plus M184V, multiple TAMs plus T69 insertion, and Q151 complex (b) favorable, safety profile in mice, rats, dogs, and cats, and (c) promising prophylactic in vivo anti-retroviral activity in Hu-PBL-SCID mice as well as therapeutic anti-retroviral activity in FIV-infected domestic cats. Notably, in a placebo-controlled Phase I study involving 30 therapy-naïve adult HIV-infected adult patients, formulated GMP- grade oral Stampidine capsules did not cause dose-limiting toxicity at single dose levels ranging from 5 to 25 mg/kg. Taken together, the presented favorable preclinical and early clinical safety/activity profile of Stampidine warrants its further development as a new anti-HIV drug candidate.

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version